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EPO and a-MSH prevent ischemia/reperfusion-induced down-
regulation of AQPs and sodium transporters in rat kidney.
Background. Ischemia-induced acute renal failure (ARF)
is known to be associated with significant impairment of uri-
nary concentrating ability and down-regulation of renal aqua-
porins (AQPs) and sodium transporters in rats. We tested
whether treatment with erythropoietin (EPO) or a-melanocyte-
stimulating hormone (a-MSH) in combination with EPO re-
duces the renal ischemia/reperfusion (I/R) injury and prevents
the down-regulation of renal AQPs and major sodium trans-
porters.
Methods. I/R-induced ARF was established in rats by 40-
minute temporary bilateral obstruction of renal arteries, and
rats were kept in metabolic cages for urine measurements. After
2 or 4 days following EPO and/or a-MSH treatment, kidneys
were removed to determine the expression levels of AQPs and
sodium transporters by semiquantitative immunoblotting.
Results. Rats with ARF showed significant renal insufficiency,
increased urine output, and high fractional excretion of urinary
sodium. Consistent with this, immunoblotting and immunocyto-
chemistry revealed that the kidney expression of AQPs (AQP-
1, -2 and -3) and sodium transporters [Na,K-ATPase, rat type
1 bumetanide-sensitive Na-K-2Cl cotransporter (BSC-1), Na/H
exchanger type 3 (NHE3), and thiazide-sensitive sodium chlo-
ride cotransporter (TSC)] in ARF rats was significantly de-
creased compared to sham-operated control rats. In contrast,
EPO treatment at the time of ischemia of rats with ARF sig-
nificantly prevented the ischemia-induced down-regulation of
renal AQPs and sodium transporters and in parallel improved
the urinary concentrating capability and renal sodium reabsorp-
tion. Importantly, similar effects were observed following the
initiation of EPO or a-MSH treatment 4 hours after the on-
set of ischemia injury. Moreover, the combination of EPO with
a-MSH potentiated the beneficial effects of single compound
treatment.
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Conclusion. EPO and/or a-MSH treatment significantly pre-
vent I/R-induced injuries such as urinary-concentrating defects
and down-regulation of renal AQPs and sodium transporters.
Experimental acute renal failure (ARF) induced by
ischemia/reperfusion (I/R) in rats manifests structural al-
terations in renal tubule epithelia in association with a
variety of functional defects, prominent among which is
an impairment of tubular reabsorption of sodium and
water [1]. In particular, the proximal tubule (especially
the S3 segment) and the outer medullary thick ascend-
ing limb (TAL) have been demonstrated to be prone to
I/R injury [2–4]. Moreover, several studies have shown
defects in the collecting duct sodium and water handling
in post-ischemic kidneys [4–7], which are associated with
urinary concentrating defects.
The aquaporins (AQPs) are a family of membrane pro-
teins that function as water channels. AQP-1 is highly
abundant in the proximal tubule and descending thin limb
and several studies have emphasized its important role in
the constitutive reabsorption of water in these segments
and its role in urinary concentration [8]. In the kidney
collecting duct at least three AQPs are known to be ex-
pressed. AQP-2 and AQP-3 are known to participate in
the vasopressin-regulated water reabsorption. AQP-2 is
the apical water channel of collecting duct principal cells
and is the chief target for regulation of collecting duct
water permeability by vasopressin [9]. Water transport
across the basolateral plasma membrane of collecting
duct principal cells is thought to be mediated by AQP-
3 [10] and AQP-4 [11]. A series of studies have demon-
strated that altered expression of renal AQPs plays a sig-
nificant role in the pathophysiology of water balance dis-
orders [12].
The renal tubular water reabsorption is driven by ac-
tive sodium transport via a variety of sodium trans-
porters. The major fraction of sodium that enters the
tubular fluid by glomerular filtration is reabsorbed at
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the kidney proximal tubule by the apical type 3 Na/H
exchanger (NHE3), basolateral Na,K-ATPase, and elec-
trogenic sodium-dependent bicarbonate cotransporter
(kNBC1). A marked decrease in the protein expression of
NHE3, Na,K-ATPase, and kNBC1 has been shown in rat
kidneys after ischemic injury [13, 14], indicating that dys-
regulation of sodium transporters could play a role in the
impaired proximal tubular sodium reabsorption in post-
ischemic kidneys. Concentration of the urine requires es-
tablishment and maintenance of a hypertonic medullary
interstitium. The loop of Henle generates a high osmo-
lality in renal medulla via the countercurrent multiplier,
which is dependent on the sodium chloride reabsorption
by the TAL [15, 16]. The rat type 1 bumetanide-sensitive
Na-K-2Cl cotransporter (BSC-1 or NKCC2), NHE3, and
Na,K-ATPase are the key components responsible for
sodium reabsorption by the TAL [16]. In the distal convo-
luted tubule, the sodium chloride cotransporter [thiazide-
sensitive sodium chloride cotransporter (TSC or NCC)] is
expressed in the apical plasma membrane domains of the
cell [17] and is involved in sodium and chloride reabsorp-
tion in this segment [18, 19]. Our previous studies have
shown that the expression of renal AQPs and sodium
transporters in rats with bilateral ischemia-induced ARF
was markedly decreased and this was associated with sig-
nificantly altered tubular water and sodium handling and
decreased urinary concentration [20, 21].
Thus, the modulation of expression of AQPs and
sodium transporters in the kidney could be a relevant
therapeutic approach in ischemia-induced ARF of hu-
man patients. We have previously demonstrated that
treatment of a-melanocyte-stimulating hormone (a-
MSH), a potent anti-inflammatory agent, significantly re-
duced the down-regulation of AQP-1, AQP-2 and AQP-3
levels as well as major renal sodium transporters (NHE3,
NaPi-2, BSC-1, TSC, and Na,K-ATPase) in rats with
bilateral ischemia-induced ARF [20, 21]. This finding
therefore suggests that inflammation and tubular cy-
tokine production may contribute to renal ischemic injury
and dysregulation of major renal transporter proteins ex-
pressed in the membrane, since a-MSH has been demon-
strated to reduce the neutrophil plugging in the medulla
and cytokine production [22]. Consistent with this, it has
also been demonstrated that the inflammatory response
to acute endotoxemia down-regulates vasopressin V2 re-
ceptors and AQP-2 of the kidney inner medulla [23]. An-
other approach for inhibiting ischemic injury in brain
has been suggested by the treatment of erythropoietin
(EPO) [24, 25]. EPO, originally identified for its criti-
cal hormonal role in promoting erythrocyte survival and
differentiation, has multiple paracrine and autocrine
functions that coordinate local responses to injury by at-
tenuating both primary (apoptotic) and secondary (in-
flammatory) causes of cell death [26]. Consistent with
this, EPO treatment of rats with cisplatin-induced ARF
enhances functional recovery [27, 28]. Since most forms
of ARF, caused by acute tubular necrosis, are associated
with a transient depression of renal EPO synthesis [29,
30], we hypothesized that EPO treatment alone or in com-
bination with a-MSH in rats with ischemia-induced ARF
may reduce the I/R injury. In the present study, we there-
fore examined whether (1) single treatment of EPO or
a-MSH or (2) combined treatment of EPO and a-MSH
reduces the renal functional defects as well as the down-
regulation of renal AQPs and sodium transporters in rats
with I/R-induced ARF. The treatment was initiated and
maintained either from the starting point of the ischemia
or from 4 hours after the development of I/R injury in rat
kidneys. The changes of renal expression of AQPs and
sodium transporters were measured by semiquantitative
immunoblotting using specific antibodies.
METHODS
Experimental animals
Studies were performed on male Munich-Wistar rats,
weighing 230 to 260 g. The animals were maintained on
standard rat chow (Altromin, Lage, Germany) and had
free access to food and water throughout the experiment.
During the entire experiment, rats were kept in individual
metabolic cages, with a 12-hour artificial light/dark cycle,
a temperature of 21 ± 2◦C, and humidity of 55 ± 2%.
Induction of ischemia-induced ARF in rats
After a period of acclimation to the metabolic cages, ex-
perimental ARF was induced by occlusion of both renal
arteries for 40 minutes. During surgery, rats were anes-
thetized with halothane (Halocarbon Laboratories, UJ,
USA) and placed on a heated table to maintain rectal
temperature at 37 to 38◦C. Both kidneys were exposed
through flank incisions, and mobilized by dissecting free
from the perirenal fat. A small portion of the renal artery
was gently dissected from the vein. The renal arteries
were occluded with a smooth surface vascular clip (60 g
pressure) (World Precision Instruments, Aston, Steve-
nage, UK) for 40 minutes. Total ischemia was confirmed
by observing blanching of the entire kidney surface. Dur-
ing the period of ischemia, the wound was closed tem-
porarily to maintain body temperature. After the clips
were removed, the kidneys were observed for an addi-
tional 2 to 5 minutes to ensure color change indicating
blood reperfusion, and the wound was closed with 3-0
silk and surgical metal clamps. The rats were returned
to metabolic cages, and 24-hour urine output and water
intake were measured daily.
As a control group, rats were subjected to sham op-
erations identical to the ones used for ARF rats without
occlusion of both renal arteries. Sham-operated rats were
monitored in parallel with rats with ARF. All rats were
killed under light halothane anesthesia, during which
time the kidneys were rapidly removed and processed
for membrane fractionation on the same day.
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Fig. 1. Diagram of study design. Ischemia-induced acute renal failure
(ARF) was established by temporary bilateral renal artery occlusion
for 40 minutes followed by reperfusion. The rats were monitored in the
following 4 or 2 days in protocol 1 and 2, respectively. Sham-operated
Clearance studies
The rats were maintained in the metabolic cages, al-
lowing quantitative urine collections and measurements
of water intake. Urine volume, osmolality, creatinine, and
sodium concentrations were measured. Plasma was col-
lected from the abdominal aorta at the time of sacrifice
for measurement of osmolality, creatinine, urea nitrogen,
and sodium concentrations.
Experimental protocol
ARF was established in rats by bilateral renal arterial
occlusion for 40 minutes followed by reperfusion. They
were then monitored for an additional 4 days (protocol
1) or 2 days (protocol 2) after ischemia (Fig. 1).
In protocol 1, the animals were divided into three
groups: (1) ARF (N = 8), (2) sham-operated control (N =
8), and (3) ARF treated with EPO (N = 8). Recombi-
nant EPO (200 U/kg, intraperitoneally) (Janssen-Cilag,
Birkerød, Denmark) was administrated at the starting
point of the ischemia, 6 and 24 hours after reperfusion,
and then every 24 hours thereafter. An additional three
rats in each group were used for immunocytochemistry.
In protocol 2, the animals were divided into five groups:
(1) ARF (N = 8), (2) sham-operated control (N = 8), (3)
ARF treated with EPO (N = 8), (4) ARF treated with
a-MSH (N = 8), and (5) ARF treated with a combina-
tion of EPO and a-MSH (N = 8). Recombinant EPO
(200 U/kg, intravenously) and/or a-MSH (200 lg/kg, in-
travenously) (Phoenix Pharmaceuticals Inc., Mountain
View, CA, USA) were given at 4 hours after reperfusion,
and then repeated 10, 24, and 48 hours after reperfusion.
The rats were sacrificed 96 hours (protocol 1) or
48 hours (protocol 2) after reperfusion. In both proto-
cols 1 and 2, vehicle (0.9% NaCl) was given to untreated
ARF and sham-operated rats.
Primary antibodies
For semiquantitative immunoblotting, we used spe-
cific antibodies to renal AQPs and sodium transporters,
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
rats were operated without artery occlusion. In protocol 1, rats were
divided into three groups: (1) ARF, (2) sham, (3) ARF treated with ery-
thropoietin (EPO) (ARF + EPO). EPO was given (intraperitoneally)
at the time of ischemia, 6-hour post-perfusion on operation day (day 0)
and then daily for 4 days. Protocol 2 rats were divided into five groups:
(1) ARF, (2) sham, (3) ARF treated with EPO (ARF + EPO), (4) ARF
treated with a-melanocyte-stimulating hormone (a-MSH) (ARF + a-
MSH), and (5) ARF treated with EPO and a-MSH (ARF + EPO +
a-MSH). EPO and/or a-MSH were given (intravenously) at 4 hours and
10 hours post-perfusion on day 0, then daily for 2 days. Vehicle (0.9%
NaCl) was administered to the untreated ARF and sham-operated rats.
Rats were maintained in metabolic cages allowing monitoring of urine
excretion rates. Urine osmolality, creatinine, urea nitrogen, and sodium
were measured. Plasma was collected at the time of sacrifice for mea-
surement of osmolality and concentrations of sodium, urea nitrogen,
and creatinine.
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which had been well characterized in previous stud-
ies: AQP-1 (RA3391/2352AP) [20], AQP-2 (LL127AP)
[9], AQP-3 (RA3040/1592AP) [20], Na,K-ATPase [21],
NHE3 (LL546AP) [31], TSC (LL573AP) [20], and BSC-
1 (LL320AP) [21].
Membrane fractionation for immunoblotting
Whole kidneys were homogenized [0.3 mol/L sucrose,
25 mmol/L imidazole, 1 mmol/L ethylenediaminete-
traacetic acid (EDTA), pH 7.2, containing 8.5 lmol/L
leupeptin and 1 mmol/L phenylmethyl sulfonylfluoride
(PMSF)] by using an ultraturrax T8 homogenizer (IKA
Labortechnik, Staufen, Germany) at maximum speed for
20 seconds, and the homogenate was centrifuged in an
Eppendorf centrifuge at 4000g for 15 minutes at 4◦C to
remove whole cells, nuclei, and mitochondria [21]. The
supernatant was then centrifuged at 200,000g for 1 hour
to produce a pellet containing membrane fractions en-
riched for both plasma membranes and intracellular vesi-
cles. Gel samples [Laemmli sample buffer containing 2%
sodium dodecyl sulphate (SDS)] were made of this pellet.
Electrophoresis and immunoblotting
Samples of membrane fractions from whole kidney
were run on 12% polyacrylamide minigels (BioRad Mini
Protean II) (Hercules, CA, USA) for AQPs, Na,K-
ATPase, and NHE3, or 9% polyacrylamide minigels for
TSC and BSC-1. For each gel an identical gel was run
in parallel and subjected to Coomassie blue staining to
ensure identical loading. The other gel was subjected to
immunoblotting. After transfer by electroelution to nitro-
cellulose membranes, blots were blocked with 5% milk
in phosphate buffered saline Tween (PBS-T) (80 mmol/L
Na2HPO4, 20 mmol/L NaH2PO4, 100 mmol/L NaCl, and
0.1% Tween 20, pH 7.5) for 1 hour, and incubated with
primary antibodies (see above) overnight at 4◦C.
The labeling was visualized with horseradish perox-
idase (HRP)-conjugated secondary antibodies (Dako,
Glostrup, Denmark) (1:3000 diluted) by using enhanced
chemiluminescence system (ECL) (Amersham Bio-
sciences, Little Chalfont, Buckinghamshire, UK). ECL
films with bands within the linear range were scanned us-
ing an AGFA scanner (Arcus II) and Corel Photopaint
software (Agfa-Gevaert A/S, Glostrup, Denmark) to con-
trol the scanner. The labeling density was quantitated
with blots, whereby samples from kidneys of rats with
ARF treated and untreated were run on each gel with
samples from kidneys of sham operated rats. The labeling
density was then corrected by densitometry of Coomassie
blue–stained gels.
Immunohistochemistry
The kidneys from ARF, EPO-treated ARF, and sham-
operated rats were fixed by retrograde perfusion via the
abdominal aorta with 3% paraformaldehyde in 0.1 mol/L
cacodylate buffer (pH 7.4). For immunoperoxidase, kid-
ney blocks containing all kidney zones were dehydrated
and embedded in paraffin. The paraffin-embedded tis-
sues were cut at 2 lm on a rotary microtome (Leica,
Heidelberg, Germany). The staining was carried out
by using indirect immunoperoxidase. The sections were
dewaxed and rehydrated, endogenous peroxidase was
blocked by 0.5% H2O2 in absolute methanol for
10 minutes at room temperature. To reveal antigens,
sections were treated with 1 mmol/L Tris solution
(pH 9.0) supplemented with 0.5 mmol/L 3,6-dioxaocta-
methylendinitrilotetraacetic acid (EGTA) and were
heated in a microwave oven for 10 minutes. Nonspe-
cific binding of immunoglobulin was prevented by in-
cubating the sections in 50 mmol/L NH4Cl for 30 min-
utes followed by blocking in PBS supplemented with 1%
bovine serum albumin (BSA), 0.05% saponin, and 0.2%
gelatin. Sections were incubated overnight at 4◦C with
primary antibodies diluted in PBS supplemented with
0.1% BSA and 0.3% Triton X-100. After rinsing with
PBS supplemented with 0.1% BSA, 0.05% saponin, and
0.2% gelatin for 3 × 10 minutes, the sections were in-
cubated in HRP-conjugated immunoglobulin (P447 or
P448, 1:200) (Dako) diluted in PBS supplemented with
0.1% BSA and 0.3% Triton X-100, followed by incuba-
tion with diaminobenzidine (DAB). The microscopy was
carried out with a Leica DMRE light microscope.
Statistical analyses
Values were presented as mean ± SE. Comparisons
between groups were made by unpaired t test. P values
< 0.05 were considered significant.
RESULTS
Renal I/R injury results in acute renal insufficiency with
impaired renal water and sodium handling (protocol 1)
As shown in Table 1, rats with temporary bilateral renal
artery occlusion for 40 minutes had significantly higher
plasma creatinine levels at day 4 after release (109 ±
35 lmol/L vs. 32 ± 1 lmol/L in sham-operated controls,
P < 0.05). Parallel to this, creatinine clearance was signif-
icantly decreased after renal I/R (3.2 ± 0.8 mL/min/kg vs.
5.6 ± 0.5 mL/min/kg in sham-operated controls, P < 0.05)
(Table 1), indicating that renal I/R resulted in acute renal
insufficiency, consistent with previous studies [20–22].
Rats with ARF induced by I/R (protocol 1) demon-
strated significantly increased urine output (Fig. 2A), in
association with a marked reduction in urine osmolality
(Fig. 2B). Consistent with the changes in urine osmolality,
the urine-to-plasma osmolality ratio (U/P osmolality) was
reduced to 2.5 ± 0.5 vs. 5.6 ± 0.5 in sham-operated con-
trols (P < 0.05) (Table 1). The marked decrease in urine
osmolality and U/P osmolality ratio indicate that ARF is
associated with reduced urinary concentrating ability. In
addition, rats with ARF revealed a significant increase
in the fractional urinary excretion of sodium (FENa,
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Table 1. Changes in renal function 4 days after release of 40-minute
bilateral renal ischemia with or without erythropoietin (EPO)
treatment (protocol 1)
ARF EPO Sham
Parameter (N = 8) (N = 8) (N = 8)
Body weight g 244 ± 2a 244 ± 4a 258 ± 4
Plasma sodium mmol/L 140 ± 0.5 139 ± 0.7 140 ± 0.5
Plasma creatinine lmol/L 109 ± 35a 46 ± 6a,b 32 ± 1
Creatine clearance 3.2 ± 0.8a 4.3 ± 0.6 5.6 ± 0.5
mL/min/kg
Fractional excretion 2.3 ± 0.9a 0.9 ± 0.1 0.7 ± 0.1
of sodium %
Urine osmolality 813 ± 151a 1355 ± 113b 1745 ± 151
mosmol/kg H2O
Urine-to-plasma osmolality 2.5 ± 0.5a 4.3 ± 0.4b 5.6 ± 0.5
ARF is rats with 40-minute bilateral ischemia-induced acute renal failure.
Values are mean ± standard errors.
aP < 0.05, when treated or untreated ARF groups were compared with sham
group.
bP < 0.05, when EPO treated ARF group was compared with ARF group.
2.3 ± 0.9% vs. 0.7 ± 0.1% in sham-operated controls, P <
0.05) (Table 1), which suggests that the tubular sodium re-
absorption of the filtered sodium is significantly impaired
in post-ischemic kidneys. This is also consistent with pre-
vious studies [21].
Functional protection against renal I/R injury by EPO
(protocol 1)
ARF rats treated with EPO at the time of ischemia
had significantly lower plasma creatinine levels (46 ±
6 lmol/L, P < 0.05), compared with untreated ARF rats
(109 ± 35 lmol/L) (Table 1). Consistent with this, the
creatinine clearance in EPO-treated rats was significantly
higher compared with untreated ARF rats and was simi-
lar to the sham-operated control level [4.3 ± 0.6 in EPO
vs. 5.6 ± 0.5 in sham-operated controls, not significant
(NS)] (Table 1). Thus EPO treatment markedly inhibits
the decline of the glomerular filtration rate (GFR) in re-
sponse to renal I/R.
Furthermore, EPO treatment reduced the degree of
polyuria that was encountered in the post-ischemic pe-
riod (Fig. 2A). Consistent with this, urine osmolality and
U/P osmolality ratio were significantly higher in EPO-
treated ARF rats, compared with untreated ARF rats
(Table 1) (Fig. 2B). EPO treatment also normalized the
increased fractional urinary excretion of sodium, which
was seen in untreated ARF rats, to the sham-operated
control level (0.9 ± 0.1% in EPO-treated ARF vs. 0.7 ±
0.1% in sham rats, NS) (Table 1). The data suggest that
EPO reduces the ischemia-induced defects in urinary
concentration and normalizes the altered renal sodium
handling in response to renal I/R.
EPO treatment prevents ischemia-induced
down-regulation of renal AQPs (protocol 1)
Figure 3 shows the effects of EPO treatment on the
renal AQP-2 and AQP-3 levels. Rats with ARF demon-
strated markedly decreased AQP-2 levels (32 ± 11% of
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Fig. 2. Effect of erythropoietin (EPO) treatment on the changes in
urine output and urine osmolality in rats with acute renal failure
(ARF) (4 days after 40-minute bilateral renal ischemia). (A) Urine
output was significantly increased after 40-minute bilateral renal is-
chemia in ARF rats. ARF rats treated with EPO showed a reduced
urine output compared with untreated ARF rats. (B) Urine osmo-
lality was significantly decreased in ARF rats. ARF rats treated with
EPO showed a significantly higher urine osmolality compared with
untreated ARF rats. ∗P < 0.05, compared with sham-operated rats;
#P < 0.05, compared with untreated ARF rats.
sham levels, P < 0.05) compared with sham-operated rats
(100 ± 10%) (Fig. 3A and B). In contrast, EPO treatment
prevented the reduction of AQP-2 expression, and ARF
rats treated with EPO had almost threefold higher AQP-
2 expression levels compared with untreated ARF rats
(Table 2) (Fig. 3A and B).
Next, we examined whether the down-regulation of
AQP-3 and AQP-1 in ARF rats was also prevented by
EPO. Similar to the observation of a change in AQP-
2 expression, expression of collecting duct AQP-3 was
approximately threefold higher in EPO-treated ARF rats
compared with untreated ARF rats (Table 2) (Fig. 3C
and D), and this expression was not different from the
levels in sham-operated rats. Also AQP-1 expression was
markedly increased (twofold) in EPO-treated ARF rats,
compared with untreated ARF rats (Table 2) (Fig. 4).
The data demonstrate that EPO treatment dramati-
cally prevents the down-regulation of renal AQPs after
renal I/R, and this is consistent with an improvement in
urinary concentrating ability in response to EPO treat-
ment in rats with ARF (Table 1).
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Fig. 3. Effect of erythropoietin (EPO) treat-
ment on collecting duct aquaporin (AQP)
(AQP-2 and AQP-3) levels in rats with acute
renal failure (ARF) (protocol 1). (A and C)
Immunoblots were reacted with anti-AQP-2
and anti-AQP-3 antibodies, which reveals 29
kD and 35 to 50 kD of AQP-2 and AQP-3
bands, representing nonglycosylated and gly-
cosylated forms of AQP-2 (A) and AQP-3
(C), respectively. (B and D) Densitometric
analysis of all samples from ARF induced by
40-minute bilateral renal ischemia, either in
absence of EPO treatment (ARF) or with
EPO treatment (EPO), and sham-operated
(sham) rats. In the absence of EPO treatment,
rats with ARF had significantly decreased
AQP-2 and AQP-3 expression levels. AQP-
2 and AQP-3 expression was markedly higher
in response to EPO treatment of ARF rats
compared with untreated rats. There was no
difference in AQP-2 and AQP-3 expression
between EPO-treated ARF rats and sham-
operated rats. ∗P < 0.05, compared with sham-
operated rats; #P < 0.05, compared with un-
treated ARF rats.
EPO treatment prevents ischemia-induced
down-regulation of sodium transporters (protocol 1)
As shown in Figure 5, Na,K-ATPase expression was
markedly decreased in ARF rats (12 ± 9% of sham lev-
els, P < 0.05) compared with sham operated rats (100 ±
12%) (Table 2). In contrast, EPO treatment signifi-
cantly prevented the decrease in the expression of Na,K-
ATPase after renal I/R (Table 2) (Fig. 5A and B). Figure 5
also shows decreased expression of NHE3, which is local-
ized in the apical domains of proximal tubule and TAL,
in untreated ARF rats (43 ± 13% of sham levels, P <
0.05) compared with sham-operated rats (100 ± 15%)
(Fig. 5C and D). In contrast, EPO treatment in ARF rats
completely restored the NHE3 expression to the sham-
operated control level (Fig. 5C and D). Moreover, the
expression level of TSC in ARF rats (51 ± 15% of sham
levels, P < 0.05) was significantly decreased compared
with sham-operated rats (100 ± 10%) (Fig. 6A and B),
whereas EPO treatment in ARF rats completely restored
the TSC expression to the sham-operated control level
(Fig. 6A and B).
Therefore, EPO treatment significantly prevents the
decrease in the expression of all the investigated sodium
transporters following renal I/R and this is consistent with
a functional improvement of renal sodium handling in
response to EPO treatment of rats with ARF (Table 1).
EPO treatment prevents ischemia-induced
down-regulation of AQPs and sodium transporters
evaluated by immunohistochemistry (protocol 1)
Comparing to the abundant labeling of AQP-1 seen in
the apical and basolateral plasma membranes of cortical
proximal tubules from sham-operated kidneys (Fig. 7A),
immunohistochemistry confirmed that AQP-1 labeling
in proximal tubules from kidneys of rats with ischemia-
induced ARF was dramatically reduced (Fig. 7B). In
Table 2. Densitometric analysis of immunoblots from acute renal
failure (ARF), ARF + erythropoietin (EPO), and sham-operated rats
Parameter ARF (N = 8) EPO (N = 8) Sham (N = 8)
AQP-2 % 32 ± 11a 92 ± 13b 100 ± 10
AQP-3 % 39 ± 16a 98 ± 24b 100 ± 7
AQP-1 % 21 ± 11a 47 ± 7a,b 100 ± 11
Na,K-ATPase % 12 ± 9a 77 ± 22b 100 ± 12
NHE3 % 43 ± 13a 117 ± 8b 100 ± 15
TSC % 51 ± 15a 125 ± 10b 100 ± 10
AQP, aquaporin; NHE3, 3 Na/H exchanger type 3; TSC, thiazide-sensitive
sodium chloride cotransporter. For densitometry of immunoblots, AQP and
sodium transporter abundance was calculated as a fraction of the mean value
from sham-operated controls. Values are mean ± standard errors.
aP < 0.05, when treated or untreated ARF groups were compared with sham
group.
bP < 0.05, when EPO treated ARF group was compared with ARF group.
contrast treatment with EPO dramatically prevented
the down-regulation of AQP-1 in proximal tubules of
ARF kidneys (Fig. 7C). Immunohistochemistry also re-
vealed an overall decrease in BSC-1 expression in the
medullary TAL from ARF rats without EPO treatment
(Fig. 7E), in comparison to the intense BSC-1 label-
ing in apical domains of TAL from sham-operated rats
(Fig. 7D). In EPO-treated ARF rats, BSC-1 labeling in
TAL was substantially stronger compared to untreated
ARF rats and similar to the labeling observed in sham-
operated rats (Fig. 7F). Moreover, strong Na,K-ATPase
labeling was observed in the basolateral plasma mem-
brane of proximal tubules in sham-operated kidney cor-
tex (Fig. 7G). In ARF kidneys Na,K-ATPase labeling
in the proximal tubules was significantly reduced (Fig.
7H), whereas the labeling of Na,K-ATPase in the proxi-
mal tubule from EPO-treated ARF rats was at the levels
seen in controls (Fig. 7I). Thus, EPO treatment of rats
with ischemia-induced ARF dramatically prevented the
down-regulation of distinct water channels and sodium
transporters expressed in various segments of the renal
tubule as determined by immunocytochemistry (Fig. 7).
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Fig. 4. Effect of erythropoietin (EPO) treatment on aquaporin-1
(AQP-1) levels in whole kidney in rats with acute renal failure (ARF)
(protocol 1). (A) The immunoblot was reacted with AQP-1 immune
serum and revealed 29 kD and 35 to 50 kD AQP-1 bands, representing
nonglycosylated and glycosylated forms of AQP-1. (B) Densitometric
analysis of all samples from ARF, either in absence of EPO treatment
(ARF) or with EPO treatment (EPO), and sham-operated (sham) rats.
In absence of treatment, rats with ARF had a significantly decreased
AQP-1 expression level. EPO treatment reduced the decline of AQP-
1 expression in EPO-treated ARF rats compared with untreated rats.
∗P < 0.05, compared with sham-operated rats; #P < 0.05, compared
with untreated ARF rats.
Delayed treatment of EPO and/or a-MSH prevents
deterioration of renal function in ARF rats (protocol 2)
As seen in Table 3, renal dysfunction observed day 2 af-
ter release of 40-minute bilateral renal ischemia (protocol
2) was similar to that seen day 4 after release of 40-minute
ischemia (protocol 1, Table 1). ARF rats with delayed
treatment of EPO and a-MSH alone, or in combination
exhibited significantly decreased plasma creatinine levels
(50 ± 3 lmol/L in EPO treatment alone, 46 ± 6 lmol/L in
a-MSH alone, and 42 ± 3 lmol/L in EPO + a-MSH, P <
0.05 respectively), compared with untreated ARF rats
(104 ± 31 lmol/L) (Table 3). Delayed EPO treatment
initiated 4 hours after ischemic injury partly normalized
creatinine clearance compared with untreated ARF rats,
but it was not statistically significant. In contrast, the crea-
tinine clearance in ARF rats treated with a-MSH alone or
in combination treatment with EPO (5.1 ± 0.5 mL/min/kg
in a-MSH treatment alone or 5.5 ± 0.5 mL/min/kg in EPO
+ a-MSH) was significantly increased compared with un-
treated ARF rats (3.5 ± 0.6 mL/min/kg, P < 0.05 respec-
tively) (Table 3). Thus delayed treatment with a-MSH
alone or in combination with EPO markedly inhibits the
decline in renal function in response to renal ischemia
and reperfusion.
Furthermore, delayed treatment with EPO, or a-
MSH alone, or both, significantly reduced the degree of
polyuria compared to untreated ARF rats (Fig. 8A). The
urine output in EPO and a-MSH combination treated
rats was decreased to the sham-operated control level
(EPO + a-MSH treatment vs. sham-operated controls,
NS) (Fig. 8A). Consistent with this, urine osmolality and
U/P osmolality ratio were increased in rats treated with
both EPO and a-MSH, comparing to untreated ARF rats
(Table 3) (Fig. 8B). This demonstrates that the combina-
tion of EPO and a-MSH treatment is more potent than
the single treatment in normalizing the altered renal func-
tion in ARF rats. Moreover, treatment with EPO or a-
MSH alone, or in combination, reduced the increased
FENa in ARF rats to a level similar to sham-operated
rats (0.6 ± 0.09% in EPO alone, 0.6 ± 0.07% in a-MSH
alone, and 0.6 ± 0.06% in EPO + a-MSH treatment vs.
0.5 ± 0.03% in sham-operated rats, NS) (Table 3).
Delayed treatment of EPO and/or a-MSH reduces
I/R-induced down-regulation of AQP-2 and
sodium transporters (protocol 2)
Rats with ARF that were not treated demonstrated
markedly decreased AQP-2 expression levels (12 ± 6% of
sham levels, P < 0.05) compared with sham-operated rats
(100 ± 10%) (Table 4). Importantly, delayed treatment
with a-MSH alone or a combination of a-MSH and EPO
initiated 4 hours post-I/R inhibited the down-regulation
of AQP-2, compared to untreated ARF rats (Fig. 9A)
(Table 4). Moreover, delayed treatment with EPO, a-
MSH, or both also dramatically prevented the decrease
in the expression of Na,K-ATPase and BSC-1 after renal
I/R, compared to untreated ARF rats (Fig. 9B) (Table 4).
DISCUSSION
Our data demonstrate the protective effect of EPO
in renal I/R injury: (1) EPO treatment inhibited the de-
cline in renal functions and normalized the increased
urine output and FENa observed in rats with ARF; (2)
EPO treatment prevented the down-regulation of AQPs
and sodium transporters and this may play a critical role
in improving ischemia-induced urinary concentrating de-
fects and impairment of tubular sodium reabsorption; (3)
EPO and a-MSH were effective even when administered
4 hours after the onset of ischemia; and (4) combination
treatment of EPO and a-MSH was more potent in in-
hibiting the decline of renal function and preventing the
down-regulation of AQPs and sodium transporters, com-
pared to single treatment either with EPO or a-MSH.
EPO treatment inhibits the decline in
renal functions in rats with ARF
ARF, caused either by renal ischemia or nephro-
toxic agents, is typically characterized by a severe re-
duction in GFR, and a variable fall in renal blood flow.
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Fig. 5. Effect of erythropoietin (EPO) treat-
ment on the expression of Na,K-ATPase and
Na/H exchanger type 3 (NHE3) in rats with
acute renal failure (ARF) (protocol 1). (A
and C) The immunoblots were reacted with
anti-Na,K-ATPase (alpha-1 subunit) and anti-
NHE3 antibodies, and revealed a ∼96 kD
Na,K-ATPase band (A) and a ∼87 kD of
NHE3 (C) band, respectively. (B and D) Den-
sitometric analyses revealed that the abun-
dance of Na,K-ATPase and NHE3 protein
levels in whole kidney samples were sig-
nificantly decreased in ARF rats compared
with sham-operated rats. EPO treatment pre-
vented the decrease in Na,K-ATPase and
NHE3 expression and the expression was at
the same level as in sham-operated controls.
∗P < 0.05, compared with sham-operated rats;
#P < 0.05, compared with untreated ARF rats.
Characteristically, the urinary concentrating ability is sig-
nificantly decreased, and tubular reabsorption of sodium
is markedly impaired. The pathophysiology of ischemic
ARF is complex and is not well defined. Structural and
biochemical changes in the post-ischemic kidney result in
vasoconstriction, desquamation of tubular cells, intralu-
minar tubular obstruction, and transtubular backleakage
of the glomerular filtrate are pathophysiologic mecha-
nisms that have previously been reported [32]. The mech-
anisms underlying intrarenal vasoconstriction and outer
medullary hypoperfusion also remain incompletely de-
fined, but probably involve multiple factors, including
endothelin and nitric oxide imbalance [1]. Furthermore,
in the outer medulla, where tubules have high oxygen re-
quirements, ischemic injury causes swelling of endothelial
cells [33] as well as adherence of neutrophils to capillar-
ies and venules. These changes may contribute to vas-
cular congestion and hence decrease blood flow [3, 34].
The ischemic damage to the outer medulla may lead to
impaired function of the tubular cells that transverse this
region of the kidney, especially with respect to the urinary
concentrating ability [35].
In the present study, EPO was shown to have a protec-
tive effect against renal I/R injury, including the normal-
ization of the increased urine output and high FENa, and
inhibition of the down-regulation of AQPs and sodium
transporters. EPO has been effective and widely used
for the treatment of anemia associated with renal failure,
human immunodeficiency virus (HIV) infection, cancer,
and surgery in a clinically excellent safety profile [36].
In addition to its erythropoietic benefits, EPO stimulates
mitogenesis in normal cells [37], as well as inducing cell
survival and mitogenesis in injured tubular cells in vitro
[38]. In ischemia-induced ARF, renal EPO synthesis is
decreased by as yet poorly understood mechanisms [29,
30]. It has been shown that EPO expression is virtually
completely absent, while EPO receptor (EPOR) expres-
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Fig. 6. Effect of erythropoietin (EPO) treatment on renal expression
of thiazide-sensitive sodium chloride cotransporter (TSC) in rats with
acute renal failure (ARF) (protocol 1). (A) The immunoblots were re-
acted with anti-TSC antibodies and revealed a ∼165 kD broad band. (B)
Densitometric analyses revealed that TSC abundance in whole kidney
was significantly decreased in ARF rats compared with sham-operated
rats. EPO treatment significantly reduced the decline of TSC expres-
sion in rats with ARF after renal ischemia, compared with ARF rats that
were not treated with EPO. ∗P < 0.05, compared with sham-operated
rats; #P < 0.05, compared with untreated ARF rats.
sion is well maintained up to 24 hours after reperfusion in
rats with ischemia-induced ARF [38]. Moreover, the de-
crease of EPO levels in human patients with ARF [39, 40]
indicates that correction of diminished EPO production
in ARF by the administration of exogenous EPO might
potentially up-regulate the EPO/EPOR system and
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Fig. 7. Immunoperoxidase localization of aquaporin-1 (AQP-1), BSC-1, and Na,K-ATPase in kidney from acute renal failure (ARF), sham-
operated, and erythropoietin (EPO)-treated ARF rats. (A and B) Abundant labeling of AQP-1 is associated with apical and basolateral plasma
membranes of proximal tubules (PT) in sham-operated rat kidneys. In kidney cortex from rats with ARF, there was a marked reduction in the
AQP-1 labeling of proximal tubule. (C) In EPO-treated ARF rats, AQP-1 labeling is slightly reduced compared with sham controls. (D and E) In
sham-operated rats, BSC-1 labeling is associated with the apical plasma membrane domains of thick ascending limb (TAL). A marked decrease in
BSC-1 labeling is seen in the medullary TAL from ARF rats without EPO treatment. (F) Comparing to sham, BSC-1 labeling in TAL was slightly
decreased in EPO-treated ARF rats. (G and H) In sham-operated rats Na,K-ATPase labeling was intensive in the basolateral membranes of proximal
tubules. Na,K-ATPase labeling was significantly reduced in the proximal tubules from ARF kidney cortex. (I) Compared with sham-operated rats,
Na,K-ATPase labeling in proximal tubules was almost unchanged in EPO-treated ARF rats (magnification ×630).
enhance the recovery against I/R injury. In the present
study, bilateral renal ischemia-induced ARF was induced
in rats by 40-minute bilateral occlusion of the renal arter-
ies and reperfusion for 2 to 4 days in order to produce le-
sions resembling those of human ARF. It has been shown
that recovery of the renal function in cisplatin-induced
ARF is significantly enhanced by EPO, which is likely in
part to act as a growth factor on tubular cells to stimu-
late cell regeneration [27]. We found that EPO treatment
resulted in a very significant protection of renal function
in ischemia-induced ARF. This suggests that administra-
tion of EPO in ARF may inhibit the loss of renal func-
tion by anti-inflammatory actions, by reducing apoptosis
[41, 42], and promote functional recovery by stimulat-
ing cell migration and cell proliferation [38]. However,
to our knowledge it has not previously been demon-
strated that EPO inhibits the down-regulation of key
transporter membrane proteins and prevents functional
deterioration in renal I/R injury. Our data demonstrate
that EPO treatment in ARF rats significantly prevents
the ischemia-induced urinary concentrating defects, the
impairment of tubular sodium reabsorption and down-
regulation of key AQPs and sodium transporters. Hence,
it partially contributes to the inhibition of functional de-
fects associated with I/R-induced ARF.
EPO treatment inhibits down-regulation
of AQP-2, AQP-3, and AQP-1
The proximal tubule (especially, in S3 segment) and
TAL are known to be the main sites of ischemic insult,
whereas collecting ducts are generally considered to be
relatively invulnerable. Nevertheless, we demonstrated
that ischemia-induced ARF is associated with markedly
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Table 3. Changes in renal function 2 days after release of 40-minute bilateral renal ischemia with or without erythropoietin (EPO) and
a-melanocyte-stimulating hormone (a-MSH) treatment (protocol 2)
Parameter ARF (N = 8) EPO (N = 8) a-MSH (N = 8) EPO + a-MSH (N = 8) Sham (N = 8)
Body weight g 236 ± 4a 237 ± 4a 246 ± 5 238 ± 2a 249 ± 3
Plasma sodium mmol/L 137 ± 0.4 137 ± 0.3 137 ± 0.5 136 ± 0.4 137 ± 0.3
Plasma creatinine lmol/L 104 ± 31a 50 ± 3a,b 46 ± 6a,b 42 ± 3a,b 32 ± 1
Creatinine clearance mL/min/kg 3.5 ± 0.6a 4.6 ± 0.4a 5.1 ± 0.5a,b 5.5 ± 0.5a,b 7.0 ± 0.2
Fractional excretion of sodium % 1.2 ± 0.27a 0.6 ± 0.09 0.6 ± 0.07 0.6 ± 0.06b 0.5 ± 0.03
Urine osmolality mosmol/kg H2O 837 ± 89a 971 ± 78a,c 1039 ± 81a 1195 ± 80a,b 1740 ± 131
Urine-to-plasma osmolality 2.7 ± 0.3a 3.2 ± 0.3a 3.4 ± 0.3a 4.0 ± 0.3a,b 5.7 ± 0.3
ARF, rats with 40-minute bilateral ischemia-induced acute renal failure. Values are mean ± standard errors.
aP < 0.05, when treated or untreated ARF groups were compared with sham group.
bP < 0.05, when treated ARF groups were compared with untreated ARF group.
cP < 0.05, compared with ARF rats treated with EPO + a-MSH.
reduced collecting duct water channel AQP-2 and AQP-3
levels with decreased urine osmolality after the ischemic
insult, which is consistent with our previous studies [20,
21]. The collecting duct represents the final site for the
control of water excretion into the urine. Water per-
meability of the collecting duct is tightly regulated, un-
der the control of the antidiuretic hormone, vasopressin,
which causes a dramatic increase in collecting duct wa-
ter permeability, allowing reabsorption of water from
the tubular fluid down an osmotic gradient [12, 16]. The
acute vasopressin-induced increase in collecting duct wa-
ter reabsorption has been shown to involve vasopressin-
regulated trafficking of AQP-2 between intracellular
vesicles and the apical plasma membrane. Long-term reg-
ulation of AQP-2 involves mechanisms that alter the ex-
pression of AQP-2 protein, thereby modulating the acute
response by changing the number of water channels in
the cell that can be recruited for vasopressin-regulated
trafficking [12].
We also demonstrated that the expression of proximal
tubule and descending thin limb water channel AQP-1
is significantly decreased in response to ischemic injury.
Adenosine triphosphate (ATP) is known to be required
for metabolic transformations such as protein synthe-
sis and maintenance of cellular structures. The proximal
tubule is largely dependent on oxidative metabolism for
generation of ATP, whereas the distal nephron is able to
synthesize ATP under conditions of limited oxygen avail-
ability [43]. Therefore, energy-dependent functions of the
proximal tubule may be likely to be more susceptible to
hypoxic conditions. The role of reduced AQP-1 levels in
ARF remains to be deteremined, although the observed
defect in urinary concentration in mice that lack AQP-1
[44] suggests that reduced AQP-1 may play a significant
role in urinary concentration defects in ARF.
Importantly, EPO treatment of rats with bilateral
ischemia-induced ARF significantly prevented the down-
regulation of AQP-2, AQP-3, and AQP-1 levels. This was
paralleled by the improvement of renal function. The
underlying mechanism of EPO treatment to inhibit the
down-regulation of AQPs in response to I/R injury is un-
known. However, EPO has been known to inhibit ni-
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Fig. 8. Effect of erythropoietin (EPO) and/or a-melanocyte-
stimulating hormone (a-MSH) treatment (initiated 4 hours after
reperfusion) (protocol 2) on the changes in urine output and urine
osmolality in rats with acute renal failure (ARF). (A) Urine output was
significantly increased in 40-minute bilateral renal ischemia-induced
ARF rats, compared with sham. ARF rats treated with EPO, a-MSH
alone, or with a combination of EPO and a-MSH showed a reduced
urine output compared with untreated ARF rats. (B) Urine osmolality
in rats with ARF was significantly decreased, compared with sham.
ARF rats treated with EPO + a-MSH showed a significantly higher
urine osmolality compared with untreated ARF rats. ∗P < 0.05, com-
pared with sham-operated rats; #P < 0.05, compared with untreated
ARF rats; &P < 0.05, compared with ARF rats treated with EPO +
a-MSH.
tric oxide production in response to ischemic injury [45]
and this could be involved in preventing AQP down-
regulation and renal functional defects. Nitric oxide is
a chemical form of endothelium-derived relaxing factor
which has important roles for renal hemodynamics and
renal sodium and water metabolism [46, 47]. Recently, it
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Table 4. Changes in the abundance of aquaporin2 (AQP-2),
Na,K-ATPase, and BSC-1 by erythropoietin (EPO) and
a-melanocyte-stimulating hormone (a-MSH) treatment of rats with
ischemia-induced acute renal failure (ARF)
Parameter AQP-2 Na-K-ATPase BSC-1
ARF (N = 8) % 12 ± 6a 15 ± 7a 10 ± 4a
EPO (N = 8) % 27 ± 13a 62 ± 23b 48 ± 21a,b
a-MSH (N = 8) % 38 ± 9a,b 78 ± 21b 63 ± 20b
EPO + a-MSH (N = 8) % 57 ± 16a,b 82 ± 16b 72 ± 21b
Sham (N = 8) % 100 ± 10 100 ± 17 100 ± 13
For densitometry of immunoblots, AQP-2, Na,K-ATPase, and BSC-1
abundance was calculated as a fraction of the mean value from sham-operated
controls. Values are means ± standard errors.
aP < 0.05, when treated or untreated ARF groups were compared with sham
group.
bP < 0.05, when treated ARF groups were compared with ARF group.
was shown directly that nitric oxide inhibits vasopressin-
stimulated osmotic water permeability in isolated and
perfused cortical collecting duct of rat kidney [46]. More-
over, Yu et al [48] demonstrated that nitric oxide pro-
duction is stimulated by the hypoxic injury in epithelial
cells, and its inhibition protects against hypoxic injury
in rat proximal tubule cells. Therefore, inhibiting nitric
oxide pathways by EPO treatment may attenuate renal
ischemic injury. Moreover, endothelin and chemokines
also have been implicated in playing a role in the urinary
concentrating defects associated with ureteral obstruc-
tion, a condition which also has been shown to be associ-
ated with reduced expression of AQP-1 to AQP-3 [49, 50].
Therefore, this raises the possibility that these mediators
may play a significant role in the dysregulation of tubu-
lar water and sodium metabolism associated with several
common pathologic conditions. EPO has also been shown
to interfere with the nuclear factor-jB (NF-jB) system
and to inhibit apoptosis by triggering cross-talk between
the signaling pathways of Janus kinase-2 (Jak-2) and NF-
jB [51]. Both mechanisms are also likely to play a role in
the effect to prevent I/R injury.
EPO treatment inhibits down-regulation
of major renal sodium transporters
We demonstrated that the expression of NHE3 and
Na,K-ATPase was significantly decreased in response to
renal I/R injury, consistent with our previous studies [21].
Since the kidney expression of NHE3 and Na,K-ATPase
is found mainly in the proximal tubule, the decreased
expression of whole kidney NHE3 and Na,K-ATPase
levels suggests that the proximal tubule sodium reab-
sorptive capacity is susceptible to I/R injury. Consistent
with this, proximal tubule reabsorption of filtered sodium
is severely compromised in post-ischemic kidney. More-
over, it is possible that the decreased expression of NHE3,
Na,K-ATPase, and AQP-1 levels in the proximal tubule
[21, 52] results in an increased delivery of sodium and wa-
ter to the distal nephron in post-ischemic kidney. How-
ever, a concomitant reduction in GFR in rats with ARF
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Fig. 9. Effect of erythropoietin (EPO) and/or a-melanocyte-
stimulating hormone (a-MSH) delay treatment on expression of
aquaporin-2 (AQP-2) and Na,K-ATPase in rats with acute renal
failure (ARF) (protocol 2). (A) Densitometric analyses revealed that
the abundance of AQP-2 in whole kidney samples was significantly
decreased in ARF rats compared to sham-operated rats. a-MSH alone
or in combination with EPO treatment prevented in part the decline
in AQP-2 expression compared with untreated rats. (B) Densitometric
analyses revealed that the abundance of the Na,K-ATPase in whole
kidney samples was significantly decreased in ARF rats compared
to sham-operated rats. EPO and/or a-MSH treatment significantly
prevented the reduction in Na,K-ATPase expression, compared
with ARF rats that were not treated. The expression levels of
Na,K-ATPase in treated rats were at the same level in comparison with
sham-operated rats. ∗P < 0.05, compared with sham-operated rats;
#P < 0.05, compared with untreated ARF rats.
and possibly tubuloglomerular feedback could reduce the
filtered load of sodium and this is consistent with the ob-
served unchanged rate of urinary sodium excretion in rats
with ARF, as observed in the previous study [21]. Thus
a significant reduction in GFR tends to prevent the ex-
tensive loss of urinary sodium that otherwise could result
from the markedly reduced abundance of sodium trans-
porters along the nephron in post-ischemic kidneys.
Importantly, both the reduced expression of sodium
transporters and the marked increase in FENa were com-
pletely prevented by treatment with EPO. This strongly
supports the view that the reduction in sodium trans-
porter expression played a significant role in the altered
tubular sodium handling. Although the underlying mech-
anisms of EPO are unknown, the role and signaling path-
ways of nitric oxide, endothelin, and chemokines could
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be associated with altering sodium transporter expres-
sion. Moreover, a direct tubular effect of EPO cannot be
excluded since Nushiro et al [53] showed that acute in-
trarenal injection of EPO stimulated a net tubular sodium
reabsorption, and reduced urine volume, and urinary ex-
cretion of sodium and potassium in anesthetized rab-
bits without effects on mean arterial pressure or renal
hemodynamics.
Delayed treatment of EPO and/or a-MSH
is still effective in reducing renal I/R injury
Ischemic renal injury is a very important cause of ARF
and the mortality of ARF patients has remained high
over the last several decades despite advances in sup-
portive care [32, 54]. Although several pharmacologic
interventions have been tried to reduce the loss of re-
nal function after renal I/R injury [32], effective thera-
peutic approaches are still needed, especially treatments
that are effective when administered after the initial is-
chemic insult. We demonstrated that EPO and a-MSH
are effective even when administered 4 hours after the
I/R. Moreover, combination treatment of EPO and a-
MSH is more potent in inhibiting the decline of renal
function and preventing the down-regulation of AQPs
and sodium transporters. Previously we and others have
demonstrated that a-MSH prevents I/R injury in rats [20–
22], even when started 6 hours after the ischemic injury in
ARF mice [22]. The effects of a-MSH are likely to be me-
diated by melanocortin receptors found on macrophages,
neutrophils, and renal tubule cells. The melanocortin re-
ceptor 1 is expressed in inflammatory cells and may me-
diate at least some of the anti-inflammatory actions of
a-MSH [55]. However, a-MSH is effective even in the
absence of neutrophils, suggesting that a-MSH also acts
directly on renal tubules [56].
Moreover, EPO has recently been used to treat
cisplatin-induced ARF in rats with significant enhance-
ment in renal function [27]. Therefore, we examined
whether delayed administration of either EPO alone or
in combination with a-MSH improve renal function in
ischemia-induced ARF. We found that administration of
either EPO or a-MSH is protective against the deteriora-
tion of renal function in ARF even by delayed administra-
tion at 4 hours after ischemia, at the time when significant
tubular necrosis is present in the ischemic kidneys [22].
The finding that the protective effect of the combina-
tion of EPO and a-MSH is more potent than the single
treatment on several parameters suggests that EPO and
a-MSH may be additive in activating the same pathways
(e.g., inhibiting the activation of NF-jB) [51, 57] as well
as working through separate mechanisms, for instance in
the inhibition of inducible nitric oxide synthase (iNOS)
[45, 58] and apoptosis [26, 41]. With the experience now
gained, further studies can be performed, to substanti-
ate this contention. This will include comparing differ-
ent doses of EPO and a-MSH in combination but also a
longer follow-up of rats to separate the possible effects
of the compounds to prevent disease progression from
enhancing recovery. On such a basis, hopefully, insights
may be gained of mechanisms and pathogenetic path-
ways which can be carried to the bedside. That will be
important studies that the experimental model used and
the results obtained in the present studies has clinical
relevance.
CONCLUSION
The ischemic insult is associated with decreased ex-
pression of the AQPs in the collecting duct and the prox-
imal tubule, as well as of several major sodium trans-
porters along the nephron in post-ischemic kidneys, coin-
ciding with the impairment of urinary concentration and
decreased tubular reabsorption of filtered sodium. EPO
treatment has a protective effect against renal I/R injury
in rat, such as normalizing the increased urine output and
high FENa and inhibiting the down-regulation of AQPs
and sodium transporters. This is the case even by delayed
administration of EPO and/or a-MSH at 4 hours of post-
perfusion. Further studies are warranted to elucidate the
underlying mechanisms for the preventing effects.
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